ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rabeprazole

Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.

Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.

Drug pageRabeprazole: every studyMany companies study it; this page follows only the 56 they lead. All 105 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 200556 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only210 open or runningphase 3since Sep 12, 2005Aug 19, 2005none ahead
Johnson & Johnson150 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Pfizerits history only40 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead
GlaxoSmithKlineits history only30 open or runningphase 4since May 14, 2015Sep 26, 2013none ahead
Viatrisits history only30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Lomond Therapeuticsits history only20 open or runningphase 1since May 1, 2024May 1, 2024none ahead
Torrent Pharmaceuticalsits history only20 open or runningphase 1since Nov 15, 2013Nov 15, 2013none ahead
Boehringer Ingelheimits history only10 open or runningphase 1since May 16, 2022May 16, 2022none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 4since May 20, 2013May 20, 2013none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Jun 15, 2015Jun 15, 2015none ahead

Also a collaborator on its studies: Ono Pharmaceutical and Pierre Fabre Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First studies: 2 phase 4 studiesFirst studyNCT00216489, NCT00216450
  2. Oct 7, 2005Phase 3 study in Gastroesophageal RefluxNCT00236392 · 422 enrolled
  3. Sep 15, 2006Phase 1 study in Gastroesophageal RefluxNCT00378287 · 37 enrolled
  4. Apr 20, 2007Phase 4 study in Gastroesophageal RefluxNCT00464308 · 1,392 enrolled · Australia
  5. Nov 1, 2007Phase 3 study in Gastroesophageal RefluxNCT00553449 · 48 enrolled
  6. Sep 4, 20082 phase 1 studies in Gastroesophageal RefluxNCT00747695, NCT00747526
  7. Nov 6, 2008Phase 3 study in Gastroesophageal RefluxNCT00787891 · 127 enrolled
  8. Mar 2, 2009Phase 1 study in Gastroesophageal RefluxNCT00855361 · 69 enrolled · United States, Germany, Poland and more
  9. Sep 4, 2009Phase 3 study in Gastroesophageal RefluxNCT00992589 · 344 enrolled · United States, Australia, Belgium and more
  10. Nov 5, 2009Phase 4 study in Esophagitis, PepticNCT01008696 · 217 enrolled
  11. Mar 11, 2010Phase 1 study in Gastroesophageal RefluxNCT01101646 · 36 enrolled · United States
  12. Aug 19, 2010Phase 1 study in HealthyNCT01186497 · 35 enrolled
  13. Oct 21, 2010Phase 1 study in HealthyNCT01241409 · 78 enrolled

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 15 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01241409Healthy1CompletedDec 201078
NCT01186497Healthy1CompletedNov 201035
NCT01101646Gastroesophageal Reflux · United States1CompletedSep 200836
NCT01008696Esophagitis, Peptic4CompletedAug 2008217
NCT00992589Gastroesophageal Reflux · United States, Australia, Belgium and more3CompletedNov 2011344
NCT00855361Gastroesophageal Reflux · United States, Germany, Poland and more1CompletedDec 201169
NCT00787891Gastroesophageal Reflux3CompletedJan 2011127
NCT00747695Gastroesophageal Reflux1Completed31
NCT00747526Gastroesophageal Reflux · United States, Belgium, Brazil and more1CompletedFeb 201251
NCT00553449Gastroesophageal Reflux3Completed48
NCT00464308Gastroesophageal Reflux · Australia4CompletedMay 20081,392
NCT00378287Gastroesophageal Reflux1Completed37
NCT00236392Gastroesophageal Reflux3Completed422
NCT00216489Gastroesophageal Reflux4Completed191
NCT00216450Helicobacter Infections4Completed80

How it is read

Names in the registry

  • “Rabeprazole”, 15 entries
  • “rabeprazole”, 14 entries
  • “rabeprazole sodium”, 10 entries
  • “E3810”, 8 entries
  • “Rabeprazole sodium”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.